Robotic Eye Surgery Platform Set for Global Rollout

ForSight Robotics secures $125M to scale its ORYOM surgery robot, targeting preventable blindness worldwide.

12 Jul 2025

ForSight Robotics just raised $125 million to take its robotic eye surgery system worldwide, betting it can help erase one of the most stubborn causes of blindness.

Cataracts remain the leading reason people lose their sight, particularly in countries with too few trained surgeons. ForSight's robot, known as ORYOM, is designed to automate delicate steps in eye surgery, delivering consistent precision where human expertise is scarce.

The Series B round, led by venture firm Eclipse, shows growing investor appetite for ultra-specialized medical robots. Unlike general surgical systems, ORYOM is built solely for eye care. It blends real-time imaging with robotic arms capable of millimeter-level accuracy, tailoring its work to a variety of clinical settings.

"Our platform is designed to deliver the highest level of surgical performance in every setting," said Dr. Joseph Nathan, co-founder and chief medical officer. "This funding accelerates our mission to bring advanced eye care to every corner of the world."

Industry watchers see the investment as a sign that narrowly focused surgical robotics is gaining momentum. Targeting a single, high-impact medical challenge can allow developers to refine performance and speed adoption, while still delivering transformative results.

Still, scaling ORYOM will require clearing regulatory hurdles, training surgeons to use the technology, and integrating it into complex healthcare systems. ForSight's sizable funding and focused mission may give it a head start on those challenges.

As healthcare systems search for smarter, more accessible solutions in the wake of the pandemic, tools like ORYOM could help rewrite the rules of surgery. If the company succeeds, its robots might do more than improve efficiency. They could prevent millions from losing their sight.